Yonsei University

Korea Research Institute of Bioscience and Biotechnology

Checkmate Therapeutics Inc.

Ewha University-Industry Collaboration Foundation

Medicinal Bioconvergence Research Center

Avixgen Inc.

Korea Health Industry Development Institute (khidi)

Snu Rdb Foundation

Yuhan Corporation

Catholic Kwandong University Industry Foundation

Gyoon Hee Han

Hwan Mook Kim

Chul Ho Lee

Hyun Seok Kim

Bum Woo Park

Chang Woo Lee

Song Kyu Park

Ki Hoon Lee

Hee Yoon Lee

Yung Hee Kho

Dong Kyu Ryu

Sang Bae Han

Tae Gyu Chun

Jin Ha Lee

Sunghoon Kim

Jin Woo Choi

So Young Kim

Sun Young Kim

Kyung Seop Ahn

Sei Ryang Oh

Jin Young Lee

Tae Sun Park

Hyeong Kyu Lee

Ji Duck Kim

Jung Hee Kim

Mi Jin Kim

Doo Young Kim

Ho Jeong Kwon

Dae Gyu Kim

Joong Ku Lee

Jeom Yong Kim

Ok Kyoung Kwon

Yun Soo Bae

Yang Soo Jang

Bo Young Park

Ji Chang You

Gui Hua Quan

Sang Ku Lee

Hye Jin Jung

Jeong Jea Seo

Joo Heon Kim

Soon Ja Choi

Ho Jae Lee

Byung Sun Min

Jin Hyuk Yang

Bong Yong Lee

Doo Na Song

Koo Hwan Chung

Yong Kee Kim

Gil-Ja Jhon

Jin-Kyung Limb

Jee Sun Yang

So-Yeop Han

Hyo Kon Chun

Ki Chul Hwang

Eun Ah Kim

Guang Hai Shen

Jeung Whan Han

Gun Cheol Kim

Hea Young Park

Kyunga Yu

Hyang Woo Lee

Jae Sang Kim

Bum Woo; Park

The present invention relates to a novel compounds for inhibiting nicotinamide phosphoribosyltransferase (NamPT), a composition comprising the same, and various uses thereof.

Compound for inhibiting nicotinamide phosphoribosyltransferase and composition containing same

This application relates to a novel benzo-heterocycle derivative and more particularly, it relates a composition for preventing and treating cancer or for inhibiting metastasis comprising benzo-heterocycle derivative or pharmaceutically acceptable salts thereof as an active ingredient. The present inventors confirmed that KRS has an effect on cancer metastasis by facilitating cancer (or tumor) cell migration through interaction with 67LR, and also found that a substance inhibiting the interaction between KRS and 67LR can prevent and treat cancer by inhibiting cancer cell metastasis. Accordingly, the composition of the present invention can inhibit cancer metastasis, and thus provide a novel means for prevention and treatment of cancer.

Use of benzo-heterocycle derivatives for preventing and treating cancer or for inhibiting cancer metastasis

The present invention relates to a pharmaceutical composition for inhibiting angiogenesis and a novel sulfonyl amide derivative compound which can be useful for the prevention or treatment of angiogenesis-related diseases or disorders. Since the compound used as an active ingredient in the pharmaceutical composition of the invention is specifically bound to UQCRB and inhibits biological functions thereof, apoptosis is not induced and angiogenic responses are inhibited. Therefore, the compound used as an active ingredient in the pharmaceutical composition of the invention can be useful as an effective and safe angiogenesis inhibitory agent.

Pharmaceutical composition with enhanced efficacy for inhibiting angiogenesis

Use of a compound of Formula 1 for inducing differentiation of mesenchymal stem cells to chondrocytes, and a pharmaceutical composition for treating a cartilage disease, which includes chondrocytes in which differentiation from mesenchymal stem cells is induced by the compound of Formula 1, are provided. Differentiation of the mesenchymal stem cells treated with the compound of Formula 1 to chondrocytes is specifically induced, and thus the compound can be used to effectively treat a cartilage disease such as arthritis, cartilage damage, and a cartilage defect.

Use of compounds for inducing differentiation of mesenchymal stem cells to chondrocytes

Disclosed is a composition for preventing or treating obesity, dyslipidemia, fatty liver or diabetes, containing an indole-3-carbinol derivative as an active ingredient. The indole-3-carbinol derivative of the present disclosure can be usefully used as a pharmaceutical or functional food composition for preventing or treating obesity, dyslipidemia, fatty liver or diabetes by inhibiting differentiation of preadipocytes and reducing accumulation of triglyceride in cells.

Composition for preventing or treating obesity, dyslipidemia, fatty liver or diabetes containing indole-3-carbinol derivative as active ingredient

Disclosed are novel rhodanine derivatives which are inhibitory of HIV activity. Also provided are a method for preparing the novel rhodanine derivatives, and a pharmaceutical composition for the prevention or treatment of AIDS containing the rhodanine derivatives as active ingredients. Having high inhibitory activity against HIV, the rhodanine derivatives can be effectively used in the prophylaxis or therapy of AIDS.

Rhodanine derivatives, method for preparing same, and pharmaceutical composition for the prevention or treatment of aids containing the rhodanine derivatives as active ingredients

The present invention relates to a method for inducing the differentiation of CD34+ hematopoietic stem cells into megakaryocytes and platelets, more particularly, a method for inducing the differentiation of CD34+ hematopoietic stem cells into megakaryocytes and platelets comprising the steps of coculturing CD34+ hematopoietic stem cells with stromal cells and adding the compound of Formula 1. Further, the present invention relates to a composition for detecting the differentiation of hematopoietic stem cells into megakaryocytes and platelets, comprising an agent measuring expression level of a gene that is selected from the group consisting of KLF2 (Kiruppel-like factor2), LOC138255 (OTTHUMP00000021439), GDF15 (growth differentiation factor 15) and INHBE (inhibin, betaE), a kit comprising the composition, a method for detecting the differentiation into megakaryocytes and platelets by using the marker genes, a method for regulating the differentiation into megakaryocytes and platelets, and a method for screening a candidate compound that regulates the differentiation into megakaryocytes and platelets.

Methods for inducing the differentiation of hematopoietic stem cells into megakaryocytes and platelets, and gene controlling the differentiation

The present invention is related to new 2-oxo-cyclic compound the process for preparing them and a pharmaceutical composition comprising the same. The present invention provides a pharmaceutical composition for preventing and treating the inflammatory disease comprising the pain or inflammation caused by rheumatic disease, for example, rheumatoid arthritis, spondyloarthopathies, gout, osteoarthritis, systemic lupus erythematosus and juvenile arthritis, and inflammatory syndrome for example, from myositis, gingivitis, synovitis, ankylosing spondylitis, burstitis, burns and scar, inflammatory Crohn's disease, Types I diabetes. therefore, it can be used as the therapeutics for treating and preventing inflammatory diseases.

2-oxo-heterocyclic compounds and the pharmaceutical compositions comprising the same

The present invention relates to a composition comprising an extract of, and tiarellic acid isolated therefrom having anti-inflammatory, anti-allergic and anti-asthmatic activity. The extract ofand the tiarellic acid isolated therefrom shows the inhibitory effect on the LTCrelease in vitro test and the suppressive effect on the IgE level and the cytokine (IL-4, IL-5 and IL-13) production, airway hyperresponsiveness, and leukocyte infiltration in OVA-induced asthmatic mice. Therefore, it can be used as the therapeutics or functional health food for treating and preventing inflammatory, allergic and asthmatic disease.

[object Object]

The present invention is related to novel use of 2-oxo-heterocyclic compounds having anticancer activity and the process for preparing them and a pharmaceutical composition comprising the same. The present invention provides a pharmaceutical composition for preventing and treating the cancer disease comprising lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head and neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer or cancer of the anal region, stomach cancer, colon cancer, breast cancer, gynecologic tumors, Hodgkin's disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, sarcomas of soft tissues, cancer of the urethra, cancer of the penis, prostate cancer, chronic or acute leukemia, solid tumors of childhood, lymphocytic lymphonas, cancer of the bladder, cancer of the kidney or ureter, or neoplasms of the central nervous system, therefore, it can be used as the therapeutics for treating and preventing cancer diseases.

2-oxo-heterocyclic compounds and pharmaceutical compositions

Growing community of inventors

Gyeonggi-do, South Korea

Gyoon Hee Han